Post-Clearance Commercialization:
Why the Work Has to Start Before Your Letter Arrives

Most MedTech teams treat post-clearance commercialization as a phase that begins the day the letter arrives. The submission goes in, the company waits, and the commercial plan gets built during the wait or, more often, after the decision. That is a sequencing error, and it is an expensive one.

Consider the two clocks side by side. FDA's shared performance goal for a 510(k), the premarket notification pathway most devices use, is a total time to decision of 112 calendar days for fiscal years 2025 through 2027, counting both agency review time and sponsor response time.¹ Getting a new Category I CPT code, the procedure code a physician bills under, takes 18 to 24 months from application to effective date.² Only one of those timelines usually appears on the company's project plan.

A 510(k) clearance means FDA agrees your device is substantially equivalent to a legally marketed predicate. It does not mean a hospital will buy it, a payer will cover it, or a biller will have a code to put on the claim. Those are separate systems, each with its own calendar, and each one moves slower than the review you are waiting on.

The following post breaks down which parts of a launch actually run long, why those timelines resist compression, and how to build a plan backward from your expected decision date instead of forward from it.

The Clearance Clock and the Commercial Clock Run at Different Speeds

FDA clearance is often the fastest step in a medical device launch, not the longest. The agency's performance goal is a decision on 95% of 510(k) submissions within 90 FDA days, with the shared total time to decision goal set at 112 calendar days.¹ For a company that has run a clean submission, clearance is a known quantity with a published service level.

Payer timelines have no equivalent. A study in JAMA Health Forum tracked 64 novel technologies authorized by FDA between 2016 and 2019 that required new Medicare coverage. The median time to at least nominal coverage was 5.7 years, and only 10.9% had coverage one year after authorization.³

The same study found that manufacturer size was the variable most strongly associated with achieving coverage. Large manufacturers cleared coverage milestones at materially higher rates than small ones at every interval measured.³ Smaller companies are not losing on the science. They are losing on the calendar, because they start the payer work later and have fewer people running it in parallel.

That gap is the case for treating commercialization as a workstream that runs alongside regulatory, not behind it.

Why the Medical Device Launch Timeline Starts Two Years Before Clearance

Some of the doors you need open close before you submit. The clearest example is Medicare's Transitional Coverage for Emerging Technologies pathway, finalized by CMS in August 2024 for FDA-designated Breakthrough Devices. CMS asks manufacturers to file a non-binding letter of intent 18 to 24 months before anticipated FDA market authorization, and a formal nomination roughly 12 months before, while stating it does not expect to accept more than five candidates per year.⁴

Read that timing carefully. A company that starts thinking about Medicare on the day of clearance missed the nomination window by about a year, and the letter-of-intent window by two.

TCET is a narrow program, and most devices will never be eligible for it. The point is what the design reveals about how the payer system works. CMS built its fastest coverage pathway on the assumption that a serious manufacturer is engaged two years before it has a marketable product. Every slower pathway assumes the same thing without saying so.

The Four Workstreams That Cannot Be Compressed

Four pieces of a launch have external clocks you do not control. Each one has to be started early because no amount of budget will shorten it later.

Coding. HCPCS Level II codes, used for devices and supplies, run on two application cycles a year for non-drug items. Applications are due the first business day of January and July, and approved codes take effect the following October and April.⁵ Miss a deadline by a week and you have added six months. A Category I CPT code, if your product requires a new physician procedure code, runs 18 to 24 months.²

Coverage. Coverage is a payer's decision that a service is medically necessary for a defined population. It is separate from coding and separate from payment, and it usually requires published evidence, a written policy request, and a review cycle measured in quarters. Our post on coverage, coding, and payment walks through how the three interact.

Evidence. The clinical data that satisfies FDA is rarely the data that satisfies a payer or a hospital finance committee. Economic endpoints, comparative utilization, and site-of-care data have to be designed into studies before those studies close, which means the decision point sits well before submission.

The hospital buying process. In most health systems, a value analysis committee reviews new products on a fixed meeting schedule, and a single missed cycle can cost a quarter. We covered how those committees actually decide in our post on value analysis committee strategy.

What MedTech Commercial Readiness Looks Like at Submission

Commercial readiness at submission does not mean a hired sales force. Carrying a full quota-bearing team through an uncertain review is how companies burn runway before they have anything to sell.

It means the slow, unglamorous work is already underway. A defined first-call segment, sized and named, rather than a total addressable market slide. A reimbursement pathway documented at the code level, including which codes exist today and which have to be created. An evidence plan with the payer-facing endpoints already in it. Pricing tested against the actual budget line a hospital would pay from.

It also means the company can be found and believed. Cicada, a MedTech launch partner, organizes this work around three things: operational infrastructure, a brand that earns trust, and precision-driven market expansion. The order matters. Demand you cannot fulfill, or claims your evidence cannot support, create problems that outlast the launch.

Sequencing the Work: A Backward Plan From Your Clearance Date

The most useful planning exercise we run with clients is a backward schedule anchored to the expected decision date rather than to today. Working backward exposes the deadlines that have already passed.

T-24 to T-18 months. Payer mix and policy environment mapped. Evidence plan set with economic endpoints included. If the device carries a Breakthrough designation, the TCET letter of intent goes in this window.⁴

T-12 months. Coding gap analysis complete, with a decision on whether existing codes are adequate. CPT or HCPCS applications filed against the correct cycle.^2,5 First KOL relationships underway, on the science rather than on the product.

T-6 months. Brand, messaging, and clinical claims built and reviewed against what the submission actually supports. Target accounts named. Value analysis dossier drafted.

T-0, clearance. Announce, activate the accounts you have already been cultivating, and start the first value analysis submissions. Nothing here should be a first conversation.

T+90 days. Early adoption data collected deliberately, because the next set of committees and payers will ask for it and your own first accounts are the only place it can come from.

Companies that run this schedule are not moving faster than anyone else. They are moving earlier, which looks the same from the outside and costs far less.

Frequently Asked Questions About Post-Clearance Commercialization

Post-Clearance Commercialization Is Decided Before the Letter Arrives

Post-clearance commercialization is a misleading name for the work, because most of what determines the outcome happens on the other side of the decision. The regulatory clock is short and published. The coding, coverage, evidence, and hospital purchasing clocks are long and mostly invisible until you are standing in front of them.

The companies that launch well are not the ones that execute faster after clearance. They are the ones whose payer submissions, evidence, and first accounts were already in motion when the letter arrived. If you want help building that schedule against your own submission date, see how we work.

Related reading: Why FDA Clearance Is Just the Beginning: A Medical Device Commercialization Strategy That Actually Works